<DOC>
	<DOC>NCT02575456</DOC>
	<brief_summary>A Single-Center, Randomized, Blind, Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Adenovirus Type 5 Vector Based Ebola Virus Disease Vaccine (Ad5-EBOV) in Healthy Adults Aged Between 18 and 50 years in Sierra Leone.</brief_summary>
	<brief_title>A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged between 18 and 50 years Able to understand the content of informed consent and signed the informed consent Able and willing to complete all the secluded study process during the whole study followup period (about 6 months). Negative in HIV diagnostic blood test on day of enrollment Axillary temperature ≤37.0°C on the day of enrollment Nonpregnant females with a negative result in the urine pregnancy test on day of enrollment General good health as established by medical history and physical examination. Infected by Ebola virus (inquiry) Vaccination with other Ebola vaccine (inquiry) HIV infection or other serious immunodeficiency disease (inquiry) Allergic history of any vaccination or drugs, or allergic to any ingredient of the Ad5EBOV, such as mannitol Family history of brain or mental disease Woman who is pregnant or breastfeeding Any acute fever disease or infections in last 7 days Major congenital defects or not wellcontrolled chronic illness Asplenia or functional asplenia Platelet disorder or other bleeding disorder Faint at the sight of blood or needles. Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months Prior administration of other research medicines in last 1 month Prior administration of attenuated vaccine(s) in the last one month Prior administration of inactivated vaccine(s) in the last 14 days Any condition that in the opinion of the investigators may interfere with the participants' compliance or evaluation of study objectives</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>